Resmetirom dosing is based on actual body weight under current U.S. Rezdiffra labeling. The following information describes the reference product and is not an individualized prescription.
| Body weight | U.S. labeled Rezdiffra dose |
|---|---|
| Less than 100 kg | 80 mg once daily |
| 100 kg or more | 100 mg once daily |
Rezdiffra is supplied as tablets in 60 mg, 80 mg and 100 mg strengths.
Administration
The reference product may be taken with or without food. Tablets should be swallowed whole and should not be split, crushed or chewed.
CYP2C8 inhibitors
Strong CYP2C8 inhibitors such as gemfibrozil are not recommended with Rezdiffra. Moderate CYP2C8 inhibitors, including clopidogrel, can require dosage modification under the prescribing information.
Hepatic impairment
Current U.S. labeling advises avoiding Rezdiffra in patients with moderate or severe hepatic impairment, defined as Child-Pugh class B or C.
Dose changes
The prescribing information provides specific instructions for interacting medicines and other circumstances. Patients should not alter the dose independently.
Resiliva-specific limitation
The website identifies Resiliva as 80 mg and 100 mg, but product-specific labeling and regulatory authorization require verification. The above dosing is based on the FDA-approved resmetirom reference product.